Stop Forxiga (Dapagliflozin) Immediately in Septic Shock
Dapagliflozin must be discontinued immediately in a patient with bacteremia, UTI, and septic shock. The FDA label explicitly recommends withholding SGLT2 inhibitors in clinical situations that predispose patients to ketoacidosis, including acute febrile illness, volume depletion, and reduced caloric intake—all of which are present in septic shock 1.
Why Discontinuation is Critical
Volume Depletion and Hemodynamic Instability
SGLT2 inhibitors cause intravascular volume depletion through osmotic diuresis, which directly worsens the hemodynamic instability of septic shock 1. The FDA label specifically warns that patients with volume depletion are at increased risk for hypotension and acute kidney injury when taking dapagliflozin 1. In septic shock, where aggressive fluid resuscitation and vasopressor support are cornerstones of management per Surviving Sepsis Campaign guidelines 2, continuing a medication that promotes volume loss is counterproductive and dangerous.
Risk of Ketoacidosis
The FDA label identifies acute febrile illness, volume depletion, and reduced caloric intake as precipitating conditions for ketoacidosis in patients on SGLT2 inhibitors 1. All three conditions are present in septic shock. The label explicitly states to "withhold FARXIGA, if possible, in temporary clinical situations that could predispose patients to ketoacidosis" and to resume only "when the patient is clinically stable and has resumed oral intake" 1.
Serious UTI Complications
Multiple case reports document SGLT2 inhibitors causing severe UTIs progressing to septic shock 3, 4, 5. One case described an 80-year-old woman who developed septic shock from UTI within 2 months of starting dapagliflozin, requiring vasopressor support 3. Another documented septic shock requiring ICU admission in a patient on empagliflozin 5. The FDA has issued warnings about serious UTIs including urosepsis and pyelonephritis requiring hospitalization with SGLT2 inhibitors 1.
Clinical Management Algorithm
Immediate Actions:
- Discontinue dapagliflozin immediately
- Do NOT wait for clinical stability to make this decision
- Focus on septic shock management per Surviving Sepsis Campaign guidelines: IV antimicrobials within 1 hour, fluid resuscitation (minimum 30 mL/kg crystalloids), vasopressor support, and source control 2
Monitoring Considerations:
- Monitor for ketoacidosis even after discontinuation, as urinary glucose excretion persists for 3 days (and up to 2 weeks in some cases) after stopping dapagliflozin 1
- Assess for signs of ketoacidosis regardless of blood glucose levels (nausea, vomiting, abdominal pain, shortness of breath) 1
- Monitor renal function closely, as SGLT2 inhibitors have been associated with acute kidney injury requiring dialysis in the setting of volume depletion 1
When to Consider Restarting: The FDA label is clear: resume dapagliflozin only when the patient is clinically stable AND has resumed oral intake 1. In practical terms:
- Septic shock resolved (off vasopressors, hemodynamically stable)
- Infection cleared or adequately controlled
- Patient tolerating oral intake
- Volume status normalized
- No ongoing acute illness
Important Caveats
Do not be misled by recent observational data suggesting continuation of SGLT2 inhibitors after UTI may reduce cardiovascular/renal events 6. This study examined non-critically ill diabetic patients with simple UTIs, not patients in septic shock. The mortality and morbidity risks of continuing a volume-depleting agent during septic shock far outweigh any theoretical long-term cardiovascular benefit.
The risk-benefit calculation is unequivocal in septic shock: The immediate life-threatening risks (worsening hypotension, ketoacidosis, acute kidney injury) vastly exceed any benefit from continued SGLT2 inhibition. The FDA label's recommendation to withhold the medication in acute illness is based on these safety concerns 1.